Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
- Latest
- Trending
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Enerpac shares dropped 9% after a Q3 revenue miss despite EPS meeting expectations and improvements in gross margin and EBITDA.
CTT Pharmaceutical CEO buys $70 in stock, signaling confidence. Despite recent gains, profitability concerns remain. Investors should monitor closely.
House Bill 488 positions Louisiana as a leader in digital finance, protecting bitcoin users and resisting CBDCs. A bold move ...
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Discover Rolls-Royce's groundbreaking Micro-Reactor, a compact, zero-emission nuclear power source poised to transform energy use across industries.
Seiko Epson vs. TravelSky Technology: Seiko Epson outperforms in volatility, profitability, earnings, & dividends, making it a stronger investment.
Scott Wren from Wells Fargo warns of a market pullback. Learn how to protect your investments with diversified, strategic portfolio ...
Bharat Biotech admits patent oversight on Covaxin, pledges to include ICMR scientists in new filings to uphold transparency and legal ...
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.